Publication Shows Piclidenoson Improves Canine Osteoarthritis, Supports $325M Vetbiolix Deal
Can-Fite BioPharma published peer-reviewed data showing oral Piclidenoson at 500 µg/kg BID significantly improved LOAD and VAS pain scores in dogs with osteoarthritis with no serious adverse events. The milestone supports Vetbiolix’s Phase 2 trial and a licensing deal potentially valued at $325 million.
1. Study Publication and Efficacy Results
Can-Fite’s peer-reviewed article in Frontiers in Veterinary Science details a study in which dogs with osteoarthritis receiving oral Piclidenoson at 500 µg/kg BID experienced significant improvement in Liverpool Osteoarthritis in Dogs (LOAD) scores, Visual Analog Scale pain assessments, and veterinarian-evaluated lameness, with no serious treatment-related adverse events.
2. Licensing Agreement and Commercial Potential
Under its licensing agreement with Vetbiolix, Can-Fite stands to receive up to $325 million in upfront, milestone and royalty payments as Piclidenoson advances toward commercialization, aligning with the estimated multi-billion dollar canine osteoarthritis market.
3. Ongoing Phase 2 Trial and Next Steps
Vetbiolix is conducting an advanced Phase 2 clinical trial evaluating oral Piclidenoson in dogs with osteoarthritis, with topline results expected to further validate safety and efficacy before potential regulatory submissions for veterinary approval.
4. Market Context and Strategic Implications
Canine osteoarthritis affects millions of dogs globally and current oral therapies face safety limitations; this external validation of Piclidenoson enhances Can-Fite’s pipeline value and underscores potential revenue streams beyond human oncology and inflammatory indications.